Overview

• Pharmaceutical companies said negotiations with the administration continued past the Sept. 29 cutoff for adopting Most Favored Nation-style pricing.
• Several firms rolled out targeted measures, including Sanofi’s $35 monthly insulin offer for all U.S. patients, Novartis’s direct-to-patient program for Cosentyx, Eli Lilly’s pledge to raise some European prices, and Bristol Myers Squibb pricing a new schizophrenia drug the same in the U.S. and U.K.
• The Centers for Medicare & Medicaid Services listed the GLOBE model under regulatory review, and industry sources expect it could mirror a 2020 MFN rule that courts blocked.
• Trump announced a 100% tariff on branded or patented drug imports starting Oct. 1 unless companies are building U.S. plants, though enforcement specifics and potential trade exemptions remain unclear.
• Australia’s industry warned that U.S. benchmarking could delay launches of new medicines there, risking reduced patient access even as pharmaceuticals remain a major Australian export to the U.S.